Julian Kositza and colleagues conducted a study that revealed the effectiveness of combining Paprotrain, a specific inhibitor of KIF20A, with palbociclib, a well-known CDK4/6 inhibitor, in treating bladder cancer. The gene discussed is KIF20A; the disease is urinary bladder carcinoma.